Kazazian Asset Management LLC Increases Position in Alexion Pharmaceuticals, Inc. (ALXN)
Kazazian Asset Management LLC increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 72.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,723 shares of the biopharmaceutical company’s stock after buying an additional 2,823 shares during the quarter. Alexion Pharmaceuticals accounts for 1.2% of Kazazian Asset Management LLC’s portfolio, making the stock its 21st largest position. Kazazian Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $818,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Guardian Life Insurance Co. of America boosted its stake in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Fiduciary Trust Co. bought a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $111,000. Meeder Asset Management Inc. bought a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $111,000. Huntington National Bank grew its position in Alexion Pharmaceuticals by 1,084.6% during the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 987 shares during the last quarter. Finally, Penserra Capital Management LLC grew its position in Alexion Pharmaceuticals by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares during the last quarter. Institutional investors own 94.25% of the company’s stock.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 0.08% on Wednesday, hitting $141.37. The stock had a trading volume of 386,743 shares. The company has a market cap of $31.55 billion, a P/E ratio of 61.31 and a beta of 1.39. The company has a 50-day moving average of $140.67 and a 200-day moving average of $125.90. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s revenue was up 21.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.13 EPS. On average, equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.
WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/kazazian-asset-management-llc-increases-position-in-alexion-pharmaceuticals-inc-alxn/1608269.html.
Several research analysts have commented on the stock. SunTrust Banks, Inc. restated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reaffirmed a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Jefferies Group LLC set a $120.00 target price on shares of Alexion Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, June 8th. Six research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $157.21.
In other news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the transaction, the executive vice president now directly owns 26,704 shares in the company, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock valued at $2,416,869 in the last quarter. 4.35% of the stock is currently owned by company insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.